Your browser doesn't support javascript.
loading
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten, Stefan J; de Bruijn, Roebi; Lutz, Catrin; Badoux, Madelon; Eijkman, Timo; Chao, Xue; Ciwinska, Marta; Sheinman, Michael; Messal, Hendrik; Herencia-Ropero, Andrea; Kristel, Petra; Mulder, Lennart; van der Waal, Rens; Sanders, Joyce; Almekinders, Mathilde M; Llop-Guevara, Alba; Davies, Helen R; van Haren, Matthijs J; Martin, Nathaniel I; Behbod, Fariba; Nik-Zainal, Serena; Serra, Violeta; van Rheenen, Jacco; Lips, Esther H; Wessels, Lodewyk F A; Wesseling, Jelle; Scheele, Colinda L G J; Jonkers, Jos.
Afiliação
  • Hutten SJ; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Lutz C; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Badoux M; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Eijkman T; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Chao X; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Ciwinska M; Center for Cancer Biology, VIB, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Sheinman M; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Messal H; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain.
  • Kristel P; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Mulder L; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • van der Waal R; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Sanders J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Almekinders MM; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Davies HR; Academic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, CB2 0QQ Cambridge, UK; Early Cancer Institute, University of Cambridge, CB2 0XZ Cambridge, UK.
  • van Haren MJ; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2302 BH Leiden, the Netherlands.
  • Martin NI; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2302 BH Leiden, the Netherlands.
  • Behbod F; Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.
  • Nik-Zainal S; Academic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, CB2 0QQ Cambridge, UK; Early Cancer Institute, University of Cambridge, CB2 0XZ Cambridge, UK.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • van Rheenen J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Wessels LFA; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Diagnostic Oncology, Netherlands Cancer Institute - Antonie van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, 2333
  • Scheele CLGJ; Center for Cancer Biology, VIB, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands. Electronic address: j.jonkers@nki.nl.
Cancer Cell ; 41(5): 986-1002.e9, 2023 05 08.
Article em En | MEDLINE | ID: mdl-37116492
ABSTRACT
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer (IBC). Due to a lack of biomarkers able to distinguish high- from low-risk cases, DCIS is treated similar to early IBC even though the minority of untreated cases eventually become invasive. Here, we characterized 115 patient-derived mouse-intraductal (MIND) DCIS models reflecting the full spectrum of DCIS observed in patients. Utilizing the possibility to follow the natural progression of DCIS combined with omics and imaging data, we reveal multiple prognostic factors for high-risk DCIS including high grade, HER2 amplification, expansive 3D growth, and high burden of copy number aberrations. In addition, sequential transplantation of xenografts showed minimal phenotypic and genotypic changes over time, indicating that invasive behavior is an intrinsic phenotype of DCIS and supporting a multiclonal evolution model. Moreover, this study provides a collection of 19 distributable DCIS-MIND models spanning all molecular subtypes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda